Evolus Celebrates Third Anniversary of the Launch of Jeuveau
Evolus, Inc. is celebrating the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau (prabotulinumtoxinA-xvfs), the first neurotoxin dedicated exclusively to aesthetics. Jeuveauis used for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age.
“Evolus continues to exceed expectations and gain momentum in our third year as a commercial company,” says David Moatazedi, President and CEO of Evolus, in a news release. “Our strong results are directly linked to our singular focus on Jeuveau, building a brand for the millennial consumer, the fastest growing patient segment of neurotoxin users, and our differentiated co-branded marketing strategy with our customers. We are grateful to our customers for their confidence in Jeuveau and continued partnership.”
The company says an estimated 2 million treatments of Jeuveau have been administered by more than 7,500 purchasing customers nationwide. The accelerated growth is largely due to the adoption of a first-in-class co-branded marketing strategy, along with its cash pay business model, according to Evolus. The co-branded marketing model offers customers a wide range of advertising options, including digital ads, billboards, and most recently, streaming television advertisements, with a direct call to action to book appointments using a smartphone and QR code.
“As we celebrate three years since the launch of Jeuveau, Evolus is especially proud of our unique, co-branded marketing strategy,” sats Crystal Muilenburg, Chief Marketing Officer. “We have worked collaboratively with our customer base to launch more than 4,300 individualized campaigns, putting Jeuveau® quite literally on the map across the country.”
In the near future, Evolus leadership says it anticipates reaching several monumental milestones, including:
- The launch of its product in Europe under the brand name Nuceiva®, anticipated in Q3 2022
- The progress of its Phase 2 trial evaluating an “extra-strength,” extended duration dose of Jeuveau (anticipated completion date of early 2023)
- An expected regulatory approval in Australia in 2023, following the acceptance of its submission from the Australian Therapeutics Good Administration (TGA) in 2022
- Exploration of other products and opportunities within the medical aesthetics market, as Evolus aims to become a leading, global multi-product aesthetics company